Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-08-09
2005-08-09
Carlson, Karen Cochrane (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C530S350000, C530S370000, C530S395000, C435S007800, C435S069100, C435S320100, C536S023100, C424S093700, C424S192100
Reexamination Certificate
active
06927207
ABSTRACT:
The present invention relates to isolated mistletoe lectin polypeptides and the pharmaceutical composition comprising the polypeptides thereof. Also, the present invention relates to processes for the production of mistletoe lectin polypeptides in homologous and heterologous host systems and mistletoe lectin peptides. Further, nucleic acid molecules are provided, which encode these mistletoe lectin polypeptides, and also pharmaceutical compositions comprising mistletoe lectin nucleic acids.
REFERENCES:
patent: 6271368 (2001-08-01), Lentzen et al.
Sweeney, E. C. et al. (1993) Crystallization of the ribosome inactivating protein ML1 from Viscum album (mistletoe) complexed with beta-D-galactose. J. Mol. Biol. vol. 234, pp. 1279-1281.
Morris Peter
Stiefel Thomas
Voelter Wolfgang
Welters Peter
Biosyn Arzneimittel GmbH
Carlson Karen Cochrane
Liu Samuel Wei
Marshall & Gerstein & Borun LLP
LandOfFree
Recombinant mistletoe lectines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant mistletoe lectines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant mistletoe lectines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3517922